News

University of Naples Federico II is implementing and evaluating Proclarix® to make it available in Italy

Zurich-Schlieren, Switzerland and Naples, Italy, May 04, 2021 – The University of Naples Federico II, Italy and Proteomedix, the Swiss cancer diagnostics company, announced today that Proclarix®, a new blood-based test for prostate cancer patient management, will be clinically evaluated and made routinely available in Italy. ”Proclarix® is an innovative decision...

read more

Interim Management Statement Q1 2021: Major Advances in COVID-19 Program, Continued Progress in Oncology Pipeline

Zurich-Schlieren, Switzerland, May 04, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced today its interim management statement for the period ending March 31, 2021. “Molecular Partners continues to grow and expand the reach of...

read more

Shareholders of Molecular Partners AG Approve all Board Proposals at the Annual General Meeting; Agnete Fredriksen and Dominik Höchli elected new Board Member

Zurich-Schlieren, Switzerland, April 21, 2021. At today's AGM of Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, the shareholders of the company approved all motions proposed by the Board of Directors with a very large...

read more